C4 Therapeutics, Inc. vs. Moderna, Inc. Common Stock
C4 Therapeutics, Inc. and Moderna, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| CCCC | MRNA | |
|---|---|---|
| Market Cap | $417.06 million | $61.50 billion |
| Revenue (TTM) | $35.04 million | $2.23 billion |
| Net Income (TTM) | $-101,416,000 | $-3,151,000,000 |
MRNA leads on 2 of 3 size & scale factors.
Valuation
| CCCC | MRNA | |
|---|---|---|
| Price / Book | 1.69 | 9.10 |
| Price / Sales | 11.90 | 27.60 |
CCCC leads on 2 of 2 valuation factors.
Profitability
| CCCC | MRNA | |
|---|---|---|
| Net Margin | -289.44% | -141.43% |
| Return on Equity | -41.02% | -46.61% |
CCCC and MRNA split the profitability factors evenly.
Risk & Sentiment
| CCCC | MRNA | |
|---|---|---|
| Short Interest | 0.29% | 0.01% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: CCCC overview, CCCC financials, MRNA overview, MRNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.